| 1. Cantello BC, Cawthorne MA, Haigh D, Hindley RM, Smith SA, Thurlby PL. (1994) The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent, 4 (10): [10.1016/S0960-894X(01)80325-5] |
| 2. Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Frost Jensen A, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P.. (2003) Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar., 46 (8): [PMID:12672231] [10.1021/jm021027r] |
| 3. Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, Uchida I.. (1998) Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents., 41 (11): [PMID:9599241] [10.1021/jm970771m] |
| 4. Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, Uchida I.. (1998) Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents., 41 (11): [PMID:9599241] [10.1021/jm970771m] |
| 5. Kitajima H, Nakamura M, Tamakawa H, Goto N.. (2000) Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer., 10 (21): [PMID:11078199] [10.1016/s0960-894x(00)00491-1] |
| 6. Liu KG, Lambert MH, Ayscue AH, Henke BR, Leesnitzer LM, Oliver WR, Plunket KD, Xu HE, Sternbach DD, Willson TM.. (2001) Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight., 11 (24): [PMID:11720854] [10.1016/s0960-894x(01)00649-7] |
| 7. Henke BR, Adkison KK, Blanchard SG, Leesnitzer LM, Mook RA, Plunket KD, Ray JA, Roberson C, Unwalla R, Willson TM.. (1999) Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists., 9 (23): [PMID:10612594] [10.1016/s0960-894x(99)00603-4] |
| 8. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL.. (1994) [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents., 37 (23): [PMID:7966158] [10.1021/jm00049a017] |
| 9. Kuroda M, Mimaki Y, Sashida Y, Mae T, Kishida H, Nishiyama T, Tsukagawa M, Konishi E, Takahashi K, Kawada T, Nakagawa K, Kitahara M.. (2003) Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice., 13 (24): [PMID:14643306] [10.1016/j.bmcl.2003.09.052] |
| 10. Sauerberg P, Bury PS, Mogensen JP, Deussen HJ, Pettersson I, Fleckner J, Nehlin J, Frederiksen KS, Albrektsen T, Din N, Svensson LA, Ynddal L, Wulff EM, Jeppesen L.. (2003) Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo., 46 (23): [PMID:14584939] [10.1021/jm0309046] |
| 11. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM.. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents., 41 (25): [PMID:9836620] [10.1021/jm9804127] |
| 12. Tanis SP, Parker TT, Colca JR, Fisher RM, Kletzein RF.. (1996) Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone., 39 (26): [PMID:8978836] [10.1021/jm9605694] |
| 13. Nomura M, Kinoshita S, Satoh H, Maeda T, Murakami K, Tsunoda M, Miyachi H, Awano K.. (1999) (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents., 9 (4): [PMID:10098657] [10.1016/s0960-894x(99)00039-6] |
| 14. Willson TM, Brown PJ, Sternbach DD, Henke BR.. (2000) The PPARs: from orphan receptors to drug discovery., 43 (4): [PMID:10691680] [10.1021/jm990554g] |
| 15. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM.. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones., 39 (3): [PMID:8576907] [10.1021/jm950395a] |
| 16. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Wöldike HF, Fleckner J, Andersen AS, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM.. (2002) Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity., 45 (4): [PMID:11831892] [10.1021/jm010964g] |
| 17. Usui S, Suzuki T, Hattori Y, Etoh K, Fujieda H, Nishizuka M, Imagawa M, Nakagawa H, Kohda K, Miyata N.. (2005) Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2., 15 (6): [PMID:15745794] [10.1016/j.bmcl.2005.01.074] |
| 18. Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, Yamada S.. (2005) Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents., 15 (3): [PMID:15664804] [10.1016/j.bmcl.2004.11.053] |
| 19. Chittiboyina AG, Venkatraman MS, Mizuno CS, Desai PV, Patny A, Benson SC, Ho CI, Kurtz TW, Pershadsingh HA, Avery MA.. (2006) Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists., 49 (14): [PMID:16821769] [10.1021/jm0510880] |
| 20. Kumar R, Mittal A, Ramachandran U.. (2007) Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators., 17 (16): [PMID:17574414] [10.1016/j.bmcl.2007.05.081] |
| 21. Sundriyal S, Viswanad B, Ramarao P, Chakraborti AK, Bharatam PV.. (2008) New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies., 18 (18): [PMID:18752947] [10.1016/j.bmcl.2008.08.028] |
| 22. Acton JJ, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, McCann ME, Moller DE, Muise ES, Tan Y, Thompson JR, Wong KK, Wu M, Xu L, Meinke PT, Berger JP, Wood HB.. (2009) Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume., 52 (13): [PMID:19507861] [10.1021/jm900097m] |
| 23. Sundriyal S, Viswanad B, Bharathy E, Ramarao P, Chakraborti AK, Bharatam PV.. (2008) New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies., 18 (11): [PMID:18482837] [10.1016/j.bmcl.2008.04.072] |
| 24. Liu W, Liu K, Wood HB, McCann ME, Doebber TW, Chang CH, Akiyama TE, Einstein M, Berger JP, Meinke PT.. (2009) Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia., 52 (14): [PMID:19530681] [10.1021/jm900367w] |
| 25. Bhattarai BR, Kafle B, Hwang JS, Khadka D, Lee SM, Kang JS, Ham SW, Han IO, Park H, Cho H.. (2009) Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects., 19 (21): [PMID:19783142] [10.1016/j.bmcl.2009.09.020] |
| 26. Geldenhuys WJ, Funk MO, Barnes KF, Carroll RT.. (2010) Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET., 20 (3): [PMID:20064719] [10.1016/j.bmcl.2009.12.088] |
| 27. Furukawa A, Arita T, Satoh S, Wakabayashi K, Hayashi S, Matsui Y, Araki K, Kuroha M, Ohsumi J.. (2010) Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives., 20 (7): [PMID:20219371] [10.1016/j.bmcl.2010.02.073] |
| 28. Thieme TM, Steri R, Proschak E, Paulke A, Schneider G, Schubert-Zsilavecz M.. (2010) Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator., 20 (8): [PMID:20307981] [10.1016/j.bmcl.2010.03.008] |
| 29. Xiang H, Zhao W, Xiao H, Qian L, Yao Y, Li XB, Liao QJ.. (2010) Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities., 18 (9): [PMID:20392645] [10.1016/j.bmc.2010.03.055] |
| 30. Goebel M, Wolber G, Markt P, Staels B, Unger T, Kintscher U, Gust R.. (2010) Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode., 18 (16): [PMID:20656494] [10.1016/j.bmc.2010.06.102] |
| 31. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.. (2006) Identifying off-target effects and hidden phenotypes of drugs in human cells., 2 (6): [PMID:16680159] [10.1038/nchembio790] |
| 32. Geldenhuys WJ, Darvesh AS, Funk MO, Van der Schyf CJ, Carroll RT.. (2010) Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening., 20 (17): [PMID:20650633] [10.1016/j.bmcl.2010.06.128] |
| 33. PubChem BioAssay data set, |
| 34. Choi J, Park Y, Lee HS, Yang Y, Yoon S.. (2010) 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists., 18 (23): [PMID:21030263] [10.1016/j.bmc.2010.09.068] |
| 35. Ushiroda K, Maruta K, Kitoh M, Iwai K, Nagamine J, Tsuchida A, Taiji M, Nagata R.. (2011) Development of a new class of benzoylpyrrole-based PPARα/γ activators., 21 (1): [PMID:21130649] [10.1016/j.bmcl.2010.11.032] |
| 36. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 37. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 38. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 39. Ushiroda K, Maruta K, Takazawa T, Nagano T, Taiji M, Kohno T, Sato Y, Horai S, Yanagi K, Nagata R.. (2011) Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators., 21 (7): [PMID:21377875] [10.1016/j.bmcl.2011.02.032] |
| 40. Zhao W, Sun J, Xiang H, Zeng YY, Li XB, Xiao H, Chen DY, Ma RL.. (2011) Synthesis and biological evaluation of new flavonoid fatty acid esters with anti-adipogenic and enhancing glucose consumption activities., 19 (10): [PMID:21515060] [10.1016/j.bmc.2011.03.063] |
| 41. Casimiro-Garcia A, Filzen GF, Flynn D, Bigge CF, Chen J, Davis JA, Dudley DA, Edmunds JJ, Esmaeil N, Geyer A, Heemstra RJ, Jalaie M, Ohren JF, Ostroski R, Ellis T, Schaum RP, Stoner C.. (2011) Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ., 54 (12): [PMID:21557540] [10.1021/jm200409s] |
| 42. Hieke M, Ness J, Steri R, Greiner C, Werz O, Schubert-Zsilavecz M, Weggen S, Zettl H.. (2011) SAR studies of acidic dual γ-secretase/PPARγ modulators., 19 (18): [PMID:21873070] [10.1016/j.bmc.2011.08.003] |
| 43. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 44. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007] |
| 45. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 46. Fracchiolla G, Laghezza A, Piemontese L, Parente M, Lavecchia A, Pochetti G, Montanari R, Di Giovanni C, Carbonara G, Tortorella P, Novellino E, Loiodice F.. (2012) Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists., 20 (6): [PMID:22341573] [10.1016/j.bmc.2012.01.025] |
| 47. Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE.. (2012) Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs., 3 (1): [PMID:22282722] [10.1021/ml200196p] |
| 48. Hsieh CT, Hsieh TJ, El-Shazly M, Chuang DW, Tsai YH, Yen CT, Wu SF, Wu YC, Chang FR.. (2012) Synthesis of chalcone derivatives as potential anti-diabetic agents., 22 (12): [PMID:22608392] [10.1016/j.bmcl.2012.04.108] |
| 49. Mohammed Iqbal AK, Khan AY, Kalashetti MB, Belavagi NS, Gong YD, Khazi IA.. (2012) Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring., 53 [PMID:22575535] [10.1016/j.ejmech.2012.04.015] |
| 50. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.. (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., 25 (10): [PMID:22931300] [10.1021/tx300075j] |
| 51. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I.. (2004) Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity., 32 (1): [PMID:14977862] [10.1124/dmd.32.3.291] |
| 52. PubChem BioAssay data set, |
| 53. Lin HR.. (2012) Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists., 22 (8): [PMID:22424975] [10.1016/j.bmcl.2012.02.043] |
| 54. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.. (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions., 55 (10): [PMID:22541068] [10.1021/jm300212s] |
| 55. Hoffmann BR, El-Mansy MF, Sem DS, Greene AS.. (2012) Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity., 55 (19): [PMID:22970990] [10.1021/jm301204r] |
| 56. la Buscató E, Blöcher R, Lamers C, Klingler FM, Hahn S, Steinhilber D, Schubert-Zsilavecz M, Proschak E.. (2012) Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors., 55 (23): [PMID:23130964] [10.1021/jm301194c] |
| 57. Giampietro L, D'Angelo A, Giancristofaro A, Ammazzalorso A, De Filippis B, Fantacuzzi M, Linciano P, Maccallini C, Amoroso R.. (2012) Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs., 22 (24): [PMID:23102891] [10.1016/j.bmcl.2012.09.111] |
| 58. Sonawane LV, Bari SB. (2011) Ligand-based in silico 3D-QSAR study of PPAR- agonists, 20 (7): [10.1007/s00044-010-9428-9] |
| 59. Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.. (2013) Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ., 23 (3): [PMID:23265881] [10.1016/j.bmcl.2012.11.088] |
| 60. Ohsawa F, Yamada S, Yakushiji N, Shinozaki R, Nakayama M, Kawata K, Hagaya M, Kobayashi T, Kohara K, Furusawa Y, Fujiwara C, Ohta Y, Makishima M, Naitou H, Tai A, Yoshikawa Y, Yasui H, Kakuta H.. (2013) Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency., 56 (5): [PMID:23391145] [10.1021/jm400033f] |
| 61. Udagawa S, Sakami S, Takemura T, Sato M, Arai T, Nitta A, Aoki T, Kawai K, Iwamura T, Okazaki S, Takahashi T, Kaino M.. (2013) Discovery of novel 7-membered cyclic amide derivatives that inhibit 11beta-hydroxysteroid dehydrogenase type 1., 23 (6): [PMID:23414800] [10.1016/j.bmcl.2013.01.090] |
| 62. Ohashi M, Oyama T, Putranto EW, Waku T, Nobusada H, Kataoka K, Matsuno K, Yashiro M, Morikawa K, Huh NH, Miyachi H.. (2013) Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility., 21 (8): [PMID:23490155] [10.1016/j.bmc.2013.02.003] |
| 63. Hu X, Compton JR, Abdulhameed MD, Marchand CL, Robertson KL, Leary DH, Jadhav A, Hershfield JR, Wallqvist A, Friedlander AM, Legler PM.. (2013) 3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening., 56 (13): [PMID:23815100] [10.1021/jm4001242] |
| 64. Koppireddi S, Komsani JR, Avula S, Pombala S, Vasamsetti S, Kotamraju S, Yadla R.. (2013) Novel 2-(2,4-dioxo-1,3-thiazolidin-5-yl)acetamides as antioxidant and/or anti-inflammatory compounds., 66 [PMID:23811092] [10.1016/j.ejmech.2013.06.005] |
| 65. Gannarapu MR, Vasamsetti SB, Punna N, Royya NK, Pamulaparthy SR, Nanubolu JB, Kotamraju S, Banda N.. (2014) Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation., 75 [PMID:24531227] [10.1016/j.ejmech.2013.12.053] |
| 66. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 67. PubChem BioAssay data set, |
| 68. Gupta S, Varshney K, Srivastava R, Rahuja N, Rawat AK, Srivastava AK, Saxena AK. (2013) Identification of novel urea derivatives as PTP1B inhibitors: synthesis, biological evaluation and structureactivity relationships, 4 (10): [10.1039/C3MD00138E] |
| 69. Pferschy-Wenzig EM, Atanasov AG, Malainer C, Noha SM, Kunert O, Schuster D, Heiss EH, Oberlies NH, Wagner H, Bauer R, Dirsch VM.. (2014) Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma., 77 (4): [PMID:24597776] [10.1021/np400943b] |
| 70. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 71. Nazreen S, Alam MS, Hamid H, Yar MS, Shafi S, Dhulap A, Alam P, Pasha MA, Bano S, Alam MM, Haider S, Ali Y, Kharbanda C, Pillai KK.. (2014) Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists., 87 [PMID:25255433] [10.1016/j.ejmech.2014.09.010] |
| 72. Helal MA, Darwish KM, Hammad MA.. (2014) Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation., 24 (22): [PMID:25441945] [10.1016/j.bmcl.2014.07.043] |
| 73. Nazreen S, Alam MS, Hamid H, Yar MS, Dhulap A, Alam P, Pasha MA, Bano S, Alam MM, Haider S, Kharbanda C, Ali Y, Pillai KK.. (2014) Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression., 24 (14): [PMID:24890090] [10.1016/j.bmcl.2014.05.034] |
| 74. Liu X, Kunert O, Blunder M, Fakhrudin N, Noha SM, Malainer C, Schinkovitz A, Heiss EH, Atanasov AG, Kollroser M, Schuster D, Dirsch VM, Bauer R.. (2014) Polyyne hybrid compounds from Notopterygium incisum with peroxisome proliferator-activated receptor gamma agonistic effects., 77 (11): [PMID:25333853] [10.1021/np500605v] |
| 75. Rojas RJ, Edmondson DE, Almos T, Scott R, Massari ME.. (2015) Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques., 23 (4): [PMID:25600407] [10.1016/j.bmc.2014.12.063] |
| 76. Fan L, Wang J, Ma X, Xiao W, Li Z, Zhong G, Tang L, Wu H.. (2015) Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity., 25 (7): [PMID:25724827] [10.1016/j.bmcl.2015.02.021] |
| 77. Patel H, Sonawane Y, Jagtap R, Dhangar K, Thapliyal N, Surana S, Noolvi M, Shaikh MS, Rane RA, Karpoormath R.. (2015) Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS., 25 (9): [PMID:25851939] [10.1016/j.bmcl.2015.03.020] |
| 78. Roche carnitine palmitoyltransferase modulator screening data (supplementary data associated with the publication CHEMBL2216752)., [10.6019/CHEMBL3431459] |
| 79. Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O.. (2011) Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites., 39 (7): [PMID:21467212] [10.1124/dmd.111.039180] |
| 80. Loi CM, Smith DA, Dalvie D.. (2013) Which metabolites circulate?, 41 (5): [PMID:23454828] [10.1124/dmd.112.050278] |
| 81. Dawson S, Stahl S, Paul N, Barber J, Kenna JG.. (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans., 40 (1): [PMID:21965623] [10.1124/dmd.111.040758] |
| 82. Chadha N, Bahia MS, Kaur M, Silakari O.. (2015) Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions., 23 (13): [PMID:25890697] [10.1016/j.bmc.2015.03.071] |
| 83. Fauber BP, Gobbi A, Robarge K, Zhou A, Barnard A, Cao J, Deng Y, Eidenschenk C, Everett C, Ganguli A, Hawkins J, Johnson AR, La H, Norman M, Salmon G, Summerhill S, Ouyang W, Tang W, Wong H.. (2015) Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists., 25 (15): [PMID:26048793] [10.1016/j.bmcl.2015.05.055] |
| 84. Blöcher R, Lamers C, Wittmann SK, Merk D, Hartmann M, Weizel L, Diehl O, Brüggerhoff A, Boß M, Kaiser A, Schader T, Göbel T, Grundmann M, Angioni C, Heering J, Geisslinger G, Wurglics M, Kostenis E, Brüne B, Steinhilber D, Schubert-Zsilavecz M, Kahnt AS, Proschak E.. (2016) N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators., 59 (1): [PMID:26595749] [10.1021/acs.jmedchem.5b01239] |
| 85. Ammazzalorso A, Carrieri A, Verginelli F, Bruno I, Carbonara G, D'Angelo A, De Filippis B, Fantacuzzi M, Florio R, Fracchiolla G, Giampietro L, Giancristofaro A, Maccallini C, Cama A, Amoroso R.. (2016) Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists., 114 [PMID:26974385] [10.1016/j.ejmech.2016.02.064] |
| 86. WHO Anatomical Therapeutic Chemical Classification, |
| 87. Patel OP, Mishra A, Maurya R, Saini D, Pandey J, Taneja I, Raju KS, Kanojiya S, Shukla SK, Srivastava MN, Wahajuddin M, Tamrakar AK, Srivastava AK, Yadav PP.. (2016) Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents., 79 (5): [PMID:27136692] [10.1021/acs.jnatprod.5b00883] |
| 88. Wang L, Ladurner A, Latkolik S, Schwaiger S, Linder T, Hošek J, Palme V, Schilcher N, Polanský O, Heiss EH, Stangl H, Mihovilovic MD, Stuppner H, Dirsch VM, Atanasov AG.. (2016) Leoligin, the Major Lignan from Edelweiss (Leontopodium nivale subsp. alpinum), Promotes Cholesterol Efflux from THP-1 Macrophages., 79 (6): [PMID:27220065] [10.1021/acs.jnatprod.6b00227] |
| 89. Geldenhuys WJ, Yonutas HM, Morris DL, Sullivan PG, Darvesh AS, Leeper TC.. (2016) Identification of small molecules that bind to the mitochondrial protein mitoNEET., 26 (21): [PMID:27687671] [10.1016/j.bmcl.2016.09.009] |
| 90. Obermoser V, Urban ME, Murgueitio MS, Wolber G, Kintscher U, Gust R.. (2016) New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile., 124 [PMID:27569195] [10.1016/j.ejmech.2016.08.027] |
| 91. Kaserer T, Obermoser V, Weninger A, Gust R, Schuster D.. (2016) Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists., 124 [PMID:27560282] [10.1016/j.ejmech.2016.07.072] |
| 92. Cox JM, Chu HD, Chelliah MV, Debenham JS, Eagen K, Lan P, Lombardo M, London C, Plotkin MA, Shah U, Sun Z, Vaccaro HM, Venkatraman S, Suzuki T, Wang N, Ashley ER, Crespo A, Madeira M, Leung DH, Alleyne C, Ogawa AM, Souza S, Thomas-Fowlkes B, Di Salvo J, Weinglass A, Kirkland M, Pachanski M, Powles MA, Tozzo E, Akiyama TE, Ujjainwalla F, Tata JR, Sinz CJ.. (2017) Design, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists., 8 (1): [PMID:28105274] [10.1021/acsmedchemlett.6b00360] |
| 93. DrugMatrix, [10.6019/CHEMBL3885881] |
| 94. Obermoser V, Mauersberger R, Schuster D, Czifersky M, Lipova M, Siegl M, Kintscher U, Gust R.. (2017) Importance of 5/6-aryl substitution on the pharmacological profile of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived PPARγ agonists., 126 [PMID:27918994] [10.1016/j.ejmech.2016.11.051] |
| 95. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development., 118 (2): [PMID:20829430] [10.1093/toxsci/kfq269] |
| 96. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.. (2014) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump., 60 (3): [PMID:24799086] [10.1002/hep.27206] |
| 97. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.. (2012) Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification., 40 (12): [PMID:22961681] [10.1124/dmd.112.047068] |
| 98. Schmidt J, Rotter M, Weiser T, Wittmann S, Weizel L, Kaiser A, Heering J, Goebel T, Angioni C, Wurglics M, Paulke A, Geisslinger G, Kahnt A, Steinhilber D, Proschak E, Merk D.. (2017) A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis., 60 (18): [PMID:28845983] [10.1021/acs.jmedchem.7b00398] |
| 99. Toyota Y, Nomura S, Makishima M, Hashimoto Y, Ishikawa M.. (2017) Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression., 27 (12): [PMID:28465099] [10.1016/j.bmcl.2017.04.061] |
| 100. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 101. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 102. Szychowski KA, Leja ML, Kaminskyy DV, Kryshchyshyn AP, Binduga UE, Pinyazhko OR, Lesyk RB, Tobiasz J, Gmiński J.. (2017) Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ)., 141 [PMID:29031063] [10.1016/j.ejmech.2017.09.071] |
| 103. Taneja G, Gupta CP, Mishra S, Srivastava R, Rahuja N, Rawat AK, Pandey J, Gupta AP, Jaiswal N, Gayen JR, Tamrakar AK, Srivastava AK, Goel A.. (2017) Synthesis of substituted 2H-benzo[e]indazole-9-carboxylate as a potent antihyperglycemic agent that may act through IRS-1, Akt and GSK-3β pathways., 8 (2): [PMID:30108748] [10.1039/C6MD00467A] |
| 104. Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE, Zaldivar-Diez J, Perez C, Zuccheri G, Miti A, Feoli A, Castellano S, Petralla S, Monti B, Rossi M, Moda F, Legname G, Martinez A, Bolognesi ML.. (2018) Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors., 61 (17): [PMID:30078314] [10.1021/acs.jmedchem.8b00610] |
| 105. Zhang JQ, Li SM, Ma X, Zhong G, Chen R, Li XS, Zhu GF, Zhou B, Guo B, Wu HS, Tang L.. (2018) Discovery of tetrahydrocarbazoles with potent hypoglycemic and hypolipemic activities., 150 [PMID:29525431] [10.1016/j.ejmech.2018.02.069] |
| 106. Liu J, Su X, Li H, Fan L, Li Y, Tang X, Yan J, Chen X, Chen F, Liu J, Yang D.. (2018) Design, synthesis, and evaluation of novel l-phenylglycine derivatives as potential PPARγ lead compounds., 26 (14): [PMID:30001846] [10.1016/j.bmc.2018.07.005] |
| 107. Tanis SP, Colca JR, Parker TT, Artman GD, Larsen SD, McDonald WG, Gadwood RC, Kletzien RF, Zeller JB, Lee PH, Adams WJ.. (2018) PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development., 26 (22): [PMID:30429097] [10.1016/j.bmc.2018.10.033] |
| 108. Choung W, Jung HJ, Nam EH, Yang D, Yoo B, Choi H, Lee BR, Park M, Jang SM, Lim JS, Kim KH, Chin J, Jung K, Lee G, Kim SH.. (2018) Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan., 28 (19): [PMID:30177375] [10.1016/j.bmcl.2018.08.036] |
| 109. Rycek L, Ticli V, Pyszkowski J, Latkolik S, Liu X, Atanasov AG, Steinacher T, Bauer R, Schuster D, Dirsch VM, Schnürch M, Ernst M, Mihovilovic MD.. (2018) Stereoselective Synthesis of the Isomers of Notoincisol A: Assigment of the Absolute Configuration of this Natural Product and Biological Evaluation., 81 (11): [PMID:30362739] [10.1021/acs.jnatprod.8b00439] |
| 110. Metwally K, Pratsinis H, Kletsas D.. (2017) Novel 2,4- thiazolidinediones: Synthesis, in vitro cytotoxic activity, and mechanistic investigation., 133 [PMID:28395220] [10.1016/j.ejmech.2017.03.052] |
| 111. Yamamoto K, Tamura T, Henmi K, Kuboyama T, Yanagisawa A, Matsubara M, Takahashi Y, Suzuki M, Saito JI, Ueno K, Shuto S.. (2018) Development of Dihydrodibenzooxepine Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Ligands of a Novel Binding Mode as Anticancer Agents: Effective Mimicry of Chiral Structures by Olefinic E/ Z-Isomers., 61 (22): [PMID:30351933] [10.1021/acs.jmedchem.8b01200] |
| 112. Unpublished dataset, |
| 113. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 114. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 115. David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al. (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, [PMID:32353859] [10.1038/s41586-020-2286-9] |
| 116. Yamamoto K, Tamura T, Nakamura R, Hosoe S, Matsubara M, Nagata K, Kodaira H, Uemori T, Takahashi Y, Suzuki M, Saito JI, Ueno K, Shuto S.. (2019) Development of a novel class of peroxisome proliferator-activated receptor (PPAR) gamma ligands as an anticancer agent with a unique binding mode based on a non-thiazolidinedione scaffold., 27 (22): [PMID:31623970] [10.1016/j.bmc.2019.115122] |
| 117. Savateev K, Fedotov V, Butorin I, Eltsov O, Slepukhin P, Ulomsky E, Rusinov V, Litvinov R, Babkov D, Khokhlacheva E, Radaev P, Vassiliev P, Spasov A.. (2020) Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents., 185 [PMID:31683103] [10.1016/j.ejmech.2019.111808] |
| 118. Choung W, Jung HJ, Yang D, Nam EH, Choi H, Lee BR, Park M, Jang SM, Lim JS, Kim WS, Kim KH, Chin J, Jung K, Lee G, Hong E, Jang TH, Myung J, Kim SH.. (2019) Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR., 29 (4): [PMID:30594432] [10.1016/j.bmcl.2018.12.043] |
| 119. Ahn S, Ma CT, Choi JM, An S, Lee M, Le THV, Pyo JJ, Lee J, Choi MS, Kwon SW, Park JH, Noh M.. (2019) Adiponectin-Secretion-Promoting Phenylethylchromones from the Agarwood of Aquilaria malaccensis., 82 (2): [PMID:30672698] [10.1021/acs.jnatprod.8b00635] |
| 120. Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL.. (2020) The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease., 63 (10): [PMID:31930920] [10.1021/acs.jmedchem.9b01701] |
| 121. Geldenhuys WJ, Skolik R, Konkle ME, Menze MA, Long TE, Robart AR.. (2019) Binding of thiazolidinediones to the endoplasmic reticulum protein nutrient-deprivation autophagy factor-1., 29 (7): [PMID:30770154] [10.1016/j.bmcl.2019.01.041] |
| 122. Schoepf AM, Salcher S, Obexer P, Gust R.. (2020) Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators., 185 [PMID:31648125] [10.1016/j.ejmech.2019.111748] |
| 123. Elzahhar PA, Alaaeddine R, Ibrahim TM, Nassra R, Ismail A, Chua BSK, Frkic RL, Bruning JB, Wallner N, Knape T, von Knethen A, Labib H, El-Yazbi AF, Belal ASF.. (2019) Shooting three inflammatory targets with a single bullet: Novel multi-targeting anti-inflammatory glitazones., 167 [PMID:30818268] [10.1016/j.ejmech.2019.02.034] |
| 124. Pathania S, Narang RK, Rawal RK.. (2019) Role of sulphur-heterocycles in medicinal chemistry: An update., 180 [PMID:31330449] [10.1016/j.ejmech.2019.07.043] |
| 125. Mosure SA, Shang J, Eberhardt J, Brust R, Zheng J, Griffin PR, Forli S, Kojetin DJ.. (2019) Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone., 62 (4): [PMID:30676741] [10.1021/acs.jmedchem.8b01573] |
| 126. Xie F, Yang F, Liang Y, Li L, Xia Y, Jiang F, Liu W, Qi Y, Chowdhury SR, Xie D, Fu L.. (2019) Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors., 164 [PMID:30611982] [10.1016/j.ejmech.2018.12.032] |
| 127. Giampietro L, Laghezza A, Cerchia C, Florio R, Recinella L, Capone F, Ammazzalorso A, Bruno I, De Filippis B, Fantacuzzi M, Ferrante C, Maccallini C, Tortorella P, Verginelli F, Brunetti L, Cama A, Amoroso R, Loiodice F, Lavecchia A.. (2019) Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome., 10 (4): [PMID:30996794] [10.1021/acsmedchemlett.8b00574] |
| 128. Choung W, Yang D, Kim H, Choi H, Lee BR, Park M, Jang SM, Lim JS, Kim WS, Kim KH, Chin J, Jung K, Lee G, Hong E, Jang TH, Joo J, Hwang H, Myung J, Kim SH.. (2019) Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes., 29 (16): [PMID:31253533] [10.1016/j.bmcl.2019.06.027] |
| 129. Rana P, Will Y, Nadanaciva S, Jones LH.. (2016) Development of a cell viability assay to assess drug metabolite structure-toxicity relationships., 26 (16): [PMID:27397500] [10.1016/j.bmcl.2016.06.088] |
| 130. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 131. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 132. An S, Yu J, Choi H, Ko H, Ahn S, Shin JC, Pyo JJ, Jeong LS, Noh M.. (2020) Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ., 28 (1): [PMID:31806266] [10.1016/j.bmc.2019.115226] |
| 133. Resetar M, Liu X, Herdlinger S, Kunert O, Pferschy-Wenzig EM, Latkolik S, Steinacher T, Schuster D, Bauer R, Dirsch VM.. (2020) Polyacetylenes from Oplopanax horridus and Panax ginseng: Relationship between Structure and PPARγ Activation., 83 (4): [PMID:32129622] [10.1021/acs.jnatprod.9b00691] |
| 134. Dowarah J, Singh VP.. (2020) Anti-diabetic drugs recent approaches and advancements., 28 (5): [PMID:32008883] [10.1016/j.bmc.2019.115263] |
| 135. Gellrich L, Heitel P, Heering J, Kilu W, Pollinger J, Goebel T, Kahnt A, Arifi S, Pogoda W, Paulke A, Steinhilber D, Proschak E, Wurglics M, Schubert-Zsilavecz M, Chaikuad A, Knapp S, Bischoff I, Fürst R, Merk D.. (2020) l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ., 63 (13): [PMID:32356658] [10.1021/acs.jmedchem.9b02150] |
| 136. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 137. Ahn S,Kim J,An S,Pyo JJ,Jung D,Lee J,Hwang SY,Gong J,Shin I,Kim HP,Kim H,Noh M. (2019) 2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore., 27 (13.0): [PMID:31128991] [10.1016/j.bmc.2019.05.028] |
| 138. Norman BH. (2020) Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies., 63 (20.0): [PMID:32511920] [10.1021/acs.jmedchem.0c00524] |
| 139. Joshi H,Patil V,Tilekar K,Upadhyay N,Gota V,Ramaa CS. (2020) Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib., 30 (23.0): [PMID:32961322] [10.1016/j.bmcl.2020.127561] |
| 140. An S,Kim G,Kim HJ,Ahn S,Kim HY,Ko H,Hyun YE,Nguyen M,Jeong J,Liu Z,Han J,Choi H,Yu J,Kim JW,Lee HW,Jacobson KA,Cho WJ,Kim YM,Kang KW,Noh M,Jeong LS. (2020) Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators., 63 (24): [PMID:33325691] [10.1021/acs.jmedchem.0c01874] |
| 141. Schoepf AM,Salcher S,Obexer P,Gust R. (2020) Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells., 195 [PMID:32272420] [10.1016/j.ejmech.2020.112258] |
| 142. Lei S,Zhang D,Qi Y,Chowdhury SR,Sun R,Wang J,Du Y,Fu L,Jiang F. (2020) Synthesis and biological evaluation of geniposide derivatives as potent and selective PTPlB inhibitors., 205 [PMID:32738350] [10.1016/j.ejmech.2020.112508] |
| 143. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 144. Koriyama Y, Hori A, Ito H, Yonezawa S, Baba Y, Tanimoto N, Ueno T, Yamamoto S, Yamamoto T, Asada N, Morimoto K, Einaru S, Sakai K, Kanazu T, Matsuda A, Yamaguchi Y, Oguma T, Timmers M, Tritsmans L, Kusakabe KI, Kato A, Sakaguchi G.. (2021) Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial., 64 (4.0): [PMID:33588527] [10.1021/acs.jmedchem.0c01917] |
| 145. Schoepf AM, Salcher S, Obexer P, Gust R.. (2021) Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy., 216 [PMID:33662676] [10.1016/j.ejmech.2021.113285] |
| 146. Desai J, Patel B, Darji B, Gite A, Panchal N, Bhosale G, Shedage S, Patel S, Kadam P, Patel G, Kumar Srivastava B, Joharapurkar A, Kshirsagar S, Giri P, Bhayani H, Patel A, Ghoshdastidar K, Bandyopadhyay D, Kumar S, Jain M, Sharma R.. (2021) Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19)., 53 [PMID:34718128] [10.1016/j.bmcl.2021.128421] |
| 147. Tilekar K, Hess JD, Upadhyay N, Bianco AL, Schweipert M, Laghezza A, Loiodice F, Meyer-Almes FJ, Aguilera RJ, Lavecchia A, C S R.. (2021) Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects., 64 (10.0): [PMID:34006099] [10.1021/acs.jmedchem.1c00491] |
| 148. Wang JT, Peng JG, Xia J, Zhang JQ, Hu CJ, Zhu GF, Guo B, Tang L.. (2021) Synthesis and biological evaluation of cajanonic acid A derivatives as potential PPARγ antagonists., 52 [PMID:34626784] [10.1016/j.bmcl.2021.128410] |
| 149. Nguyen M, An S, Nguyen Y, Hyun YE, Choi H, Pham L, Kim JA, Noh M, Kim G, Jeong LS.. (2022) Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives., 13 (7.0): [PMID:35859875] [10.1021/acsmedchemlett.2c00159] |
| 150. Jadoon R, Aamir Javed M, Saeed Jan M, Ikram M, Mahnashi MH, Sadiq A, Shahid M, Rashid U.. (2022) Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors., 76 [PMID:36162779] [10.1016/j.bmcl.2022.128994] |
| 151. Kim J, Ko H, Hur JS, An S, Lee JW, Deyrup ST, Noh M, Shim SH.. (2022) Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus, Daldinia childiae., 85 (12.0): [PMID:36475432] [10.1021/acs.jnatprod.2c00791] |
| 152. Nhoek P, Ahn S, Pel P, Kim YM, Huh J, Kim HW, Noh M, Chin YW.. (2023) Alkaloids and Coumarins with Adiponectin-Secretion-Promoting Activities from the Leaves of Orixa japonica., 86 (1.0): [PMID:36529937] [10.1021/acs.jnatprod.2c00844] |
| 153. Xu XT, Shi LY, Ban YJ, Luo BL, Zhu GF, Guo B, Tang L, Sang ZP, Wang JT.. (2023) Design, synthesis and biological evaluation of cajanonic acid A analogues as potent PPAR γ antagonists., 80 [PMID:36414176] [10.1016/j.bmcl.2022.129081] |
| 154. Kerru N, Singh-Pillay A, Awolade P, Singh P.. (2018) Current anti-diabetic agents and their molecular targets: A review., 152 [PMID:29751237] [10.1016/j.ejmech.2018.04.061] |
| 155. Ahn S, Basavana Gowda MK, Lee M, Masagalli JN, Mailar K, Choi WJ, Noh M.. (2020) Novel linked butanolide dimer compounds increase adiponectin production during adipogenesis in human mesenchymal stem cells through peroxisome proliferator-activated receptor γ modulation., 187 [PMID:31865018] [10.1016/j.ejmech.2019.111969] |
| 156. Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED.. (2021) Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches., 64 (10.0): [PMID:34003642] [10.1021/acs.jmedchem.0c02245] |
| 157. Hou X, Malainer C, Atanasov AG, Heiß EH, Dirsch VM, Wang L, Wang K.. (2021) Evodiamine Lowers Blood Lipids by Up-Regulating the PPARγ/ABCG1 Pathway in High-Fat-Diet-Fed Mice., 84 (12.0): [PMID:34902249] [10.1021/acs.jnatprod.1c00881] |
| 158. Kumar V, Islam A, Hassan MI, Ahmad F.. (2016) Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning., 121 [PMID:27372371] [10.1016/j.ejmech.2016.06.017] |
| 159. An S, Ko H, Jang H, Park IG, Ahn S, Hwang SY, Gong J, Oh S, Kwak SY, Lee Y, Kim H, Noh M.. (2023) Prenylated Chrysin Derivatives as Partial PPARγ Agonists with Adiponectin Secretion-Inducing Activity., 14 (4): [PMID:37077388] [10.1021/acsmedchemlett.2c00511] |
| 160. Naim MJ, Alam MJ, Ahmad S, Nawaz F, Shrivastava N, Sahu M, Alam O.. (2017) Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship., 129 [PMID:28231521] [10.1016/j.ejmech.2017.02.031] |
| 161. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
